The Non-Malignant Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Long-term results of BELIEVE: luspatercept in adults with transfusion-dependent beta-thalassemia
Ali Taher, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, gives an overview of the mechanism of action of luspatercept and discusses the long-term results of the Phase III BELIEVE study (NCT02604433) which evaluated luspatercept in patients with transfusion-dependent beta-thalassemia. After a period of three years, the study reported a benefit for patients treated with luspatercept, with a high number of patients achieving transfusion independence. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Novartis Pharmaceuticals: Consultancy, Research funding; Bristol-Myers Squibb (Celgene): Consultancy, Research funding; Ionis Pharmaceuticals: Consultancy, Research Funding; Vifor: Consultancy, Research Funding; Imara: Consultancy, Research Funding; Agios: Consultancy
